Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | PDE6D | O43924 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3430 | 1.00 | HMGCR (0.53) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL14334566 | 1.00 | HMGCR (0.53) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL15976652 | 1.00 | HMGCR (0.53) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL16401450 | 0.93 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL15976641 | 0.93 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL7093034 | 0.93 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL18979348 | 0.92 | HMGCR (0.60) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL12609138 | 0.92 | HMGCR (0.43) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL12130486 | 0.92 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL16401418 | 0.90 | HMGCR (0.49) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009128091-A2 | CRYSTALLINE FORM OF(7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(N- METHYL-N-METHYLSULFONYLAMINO)PYRIMIDIN-5-YL]-(3R,5S)- DIHYDROXY-(E)-6-HEPTENOIC ACID INTERMEDIATE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | MATRIX LABORATORIES LIMITED (IN) | 2009-10-22 | — | — | WO | claimed |
| WO-2008093205-A2 | A METHOD FOR THE PURIFICATION OF ROSUVASTATIN INTERMEDIATE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2008-08-07 | — | — | WO | claimed |
| US-9932361-B2 | Convenient process for the preparation of statins | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2018-04-03 | — | — | US | disclosed |
| US-9932361-B2 | Convenient process for the preparation of statins | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2018-04-03 | — | — | US | disclosed |
| US-9926283-B2 | Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-9926283-B2 | Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-9850213-B2 | Method for preparing rosuvastatin sodium | JIANGXI BOYA SEEHOT PHARMACEUTICAL CO., LTD. (CN) | 2017-12-26 | — | — | US | disclosed |
| US-9850213-B2 | Method for preparing rosuvastatin sodium | JIANGXI BOYA SEEHOT PHARMACEUTICAL CO., LTD. (CN) | 2017-12-26 | — | — | US | disclosed |
| EP-3115367-B1 | INTERMEDIATE COMPOUND FOR PREPARING ROSUVASTATIN CALCIUM AND METHOD FOR PREPARING ROSUVASTATIN CALCIUM THEREFROM | ASYMCHEM LABORATORIES (TIANJIN) CO LTD (CN) | 2017-11-01 | — | — | EP | disclosed |
| US-20170183314-A1 | METHOD FOR PREPARING ROSUVASTATIN SODIUM | FUDAN UNIVERSITY (CN) | 2017-06-29 | — | — | US | disclosed |
| US-20170183314-A1 | METHOD FOR PREPARING ROSUVASTATIN SODIUM | FUDAN UNIVERSITY (CN) | 2017-06-29 | — | — | US | disclosed |
| US-20090076271-A1 | Process for preparing intermediates of HMG-CoA reductase inhibitors | TEVA PHARMACEUTICALS USA, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090076292-A1 | Rosuvastatin intermediates and process for the preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2009-03-19 | — | — | US | disclosed |
| WO-2008093205-A2 | A METHOD FOR THE PURIFICATION OF ROSUVASTATIN INTERMEDIATE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2008-08-07 | — | — | WO | disclosed |
| US-20070167625-A1 | Preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-19 | — | — | US | disclosed |
| US-20070142418-A1 | Process for the preparation of rosuvastatin | TEVA PHARMACEUTICALS USA, INC. | 2007-06-21 | — | — | US | disclosed |
| US-7179916-B2 | Process for the preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-02-20 | — | — | US | disclosed |
| US-20070037979-A1 | Preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-02-15 | — | — | US | disclosed |
| US-RE37314-E1 | Pyrimidine derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-08-07 | — | — | US | disclosed |
| US-5260440-A | Anticholesterol agents | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076271-A1 | Process for preparing intermediates of HMG-CoA reductase inhibitors | HMGCR, COASY, PCSK9 | HMGCR 1/4885ALDH1A1 1029/4885CYP3A4 62/4885 |
| US-20090076292-A1 | Rosuvastatin intermediates and process for the preparation of rosuvastatin | HMGCR, PCSK9, CYP4A11 | HMGCR 1/4885ALDH1A1 2138/4885CYP3A4 9/4885 |
| US-20170183314-A1 | METHOD FOR PREPARING ROSUVASTATIN SODIUM | HMGCR, NOX4, PTEN | HMGCR 1/4885ALDH1A1 1238/4885CYP3A4 94/4885 |
| US-20070167625-A1 | Preparation of rosuvastatin | HMGCR, PCSK9, PCSK7 | HMGCR 1/4885ALDH1A1 2701/4885CYP3A4 21/4885 |
| US-20070142418-A1 | Process for the preparation of rosuvastatin | HMGCR, PCSK9, FDPS | HMGCR 1/4885ALDH1A1 2996/4885CYP3A4 24/4885 |
| US-20070037979-A1 | Preparation of rosuvastatin | HMGCR, PCSK9, PCSK7 | HMGCR 1/4885ALDH1A1 2701/4885CYP3A4 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.